A Long-Term Safety Follow-up Registry for Patients Who Received Treatment with Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
A Long-Term Safety Follow-up Registry for Patients Who Received Treatment with Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
Why this Research Matters
Registry study for patients who received Prademagene Zamikeracel
Who can Participate
All Ages
RDEB
Study ID
Protocol Number: 24-2384
Meet the Team
Principal Investigator